Mirum Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Mirum Pharmaceuticals's estimated annual revenue is currently $86.7M per year.
- Mirum Pharmaceuticals's estimated revenue per employee is $281,400
- Mirum Pharmaceuticals's total funding is $120M.
Employee Data
- Mirum Pharmaceuticals has 308 Employees.
- Mirum Pharmaceuticals grew their employee count by 31% last year.
Mirum Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | VP | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Head Research And Development | Reveal Email/Phone |
4 | SVP, Global Controller | Reveal Email/Phone |
5 | VP, Global Supply Chain | Reveal Email/Phone |
6 | SVP and Head Global Quality | Reveal Email/Phone |
7 | SVP, Human Resources | Reveal Email/Phone |
8 | VP, General Manager, Italy & South Europe | Reveal Email/Phone |
9 | Chief Compliance Officer | Reveal Email/Phone |
10 | Chief Financial Officer | Reveal Email/Phone |
Mirum Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is Mirum Pharmaceuticals?
Mirum Pharmaceuticals (NASDAQ: MIRM) is dedicated to creating life-changing therapies for patients with liver diseases. We are advancing our lead product candidate for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) — conditions with a profound and devastating impact on quality of life for young patients and their families. Untreated, these conditions can lead to liver failure and inflict life-altering symptoms including stunted growth and severe, non-stop itching. Under current standard of care, patients often require a liver transplant and are at higher risk of many serious health issues. Working closely with patients and caregiver communities, we intimately understand the challenges of living with cholestatic liver diseases. Based on a wealth of data from clinical trials spanning multiple years and involving more than one hundred patients, we believe our approach can address the underlying cause of symptoms and liver damage. Our goal is to give families their lives back.
keywords:N/A$120M
Total Funding
308
Number of Employees
$86.7M
Revenue (est)
31%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Mirum Pharmaceuticals News
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating...
Does Mirum Pharmaceuticals Have A Long Cash Runway? A cash runway is defined as the length of time it would take a company to run out of money...
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). April 08, 2022 06:30 PM Eastern Daylight Time. FOSTER CITY, Calif.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar 10, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 10, 2021, the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 114,800 shares of common stock t ...
On December 30, 2020, Mirum Pharmaceuticals, Inc. (NasdaqGM:MIRM) closed the transaction. The company raised $10,000,000 pursuant to Regulation D from 3 investors.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $17.1M | 323 | 54% | $281M |
#2 | $71M | 327 | 16% | $384.5M |
#3 | $116.1M | 379 | N/A | N/A |
#4 | $79.5M | 424 | 5% | N/A |
#5 | $143.3M | 468 | 8% | N/A |